EA202090024A1 - Способы лечения лептоменингеального заболевания - Google Patents

Способы лечения лептоменингеального заболевания

Info

Publication number
EA202090024A1
EA202090024A1 EA202090024A EA202090024A EA202090024A1 EA 202090024 A1 EA202090024 A1 EA 202090024A1 EA 202090024 A EA202090024 A EA 202090024A EA 202090024 A EA202090024 A EA 202090024A EA 202090024 A1 EA202090024 A1 EA 202090024A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disease
methods
leptomingeal
treating
leptomeningeal
Prior art date
Application number
EA202090024A
Other languages
English (en)
Inventor
Станислав Р. Бурзинский
Original Assignee
Станислав Р. Бурзинский
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Станислав Р. Бурзинский filed Critical Станислав Р. Бурзинский
Publication of EA202090024A1 publication Critical patent/EA202090024A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Способы лечения лептоменингеального заболевания у педиатрического пациента. Лептоменингеальное заболевание может представлять собой лептоменингеальное, диссеминированное и/или мультицентрическое заболевание (LDM) и может быть связано с одной или несколькими первичными опухолями ЦНС или одной или несколькими глиомами низкой степени (LGG). Способ включает введение пациенту множества чужеродных антинеопластонов.
EA202090024A 2017-06-12 2018-06-11 Способы лечения лептоменингеального заболевания EA202090024A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762518500P 2017-06-12 2017-06-12
PCT/US2018/036972 WO2018231733A1 (en) 2017-06-12 2018-06-11 Methods for the treatment of leptomeningeal disease

Publications (1)

Publication Number Publication Date
EA202090024A1 true EA202090024A1 (ru) 2020-04-10

Family

ID=64659964

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090024A EA202090024A1 (ru) 2017-06-12 2018-06-11 Способы лечения лептоменингеального заболевания

Country Status (10)

Country Link
US (1) US11607397B2 (ru)
EP (1) EP3638224A4 (ru)
KR (2) KR20200026893A (ru)
CN (1) CN110997008A (ru)
AU (2) AU2018282735A1 (ru)
CA (1) CA3067026A1 (ru)
EA (1) EA202090024A1 (ru)
IL (1) IL272422A (ru)
MX (1) MX2019014975A (ru)
WO (1) WO2018231733A1 (ru)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258849B1 (en) * 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
TW201536278A (zh) * 2013-05-31 2015-10-01 Del Mar Pharmaceuticals 雙脫水半乳糖醇及其類似物與衍生物用於治療復發性惡性神經膠瘤或進行性繼發腦瘤之用途
EP3056216B1 (en) 2015-02-11 2017-02-01 Deutsches Krebsforschungszentrum Cancer therapy with a parvovirus combined with bevacizumab
US10624869B2 (en) 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)

Also Published As

Publication number Publication date
EP3638224A1 (en) 2020-04-22
US11607397B2 (en) 2023-03-21
US20210145776A1 (en) 2021-05-20
KR20200026893A (ko) 2020-03-11
KR20230124107A (ko) 2023-08-24
AU2024203261A1 (en) 2024-06-06
EP3638224A4 (en) 2021-02-24
CN110997008A (zh) 2020-04-10
IL272422A (en) 2020-03-31
CA3067026A1 (en) 2018-12-20
MX2019014975A (es) 2020-09-07
AU2018282735A1 (en) 2020-02-06
WO2018231733A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
PH12017502142A1 (en) Tetrasubstituted aklene compounds and their use
EA201990951A1 (ru) Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
MY179105A (en) Methods of treating alzheimer's disease
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
MX2019009190A (es) Uso de gaboxadol en el tratamiento de tinnitus.
MX2021002321A (es) Nuevos metodos.
MX2018008299A (es) Metodos para administrar hepcidina.
EA201991650A1 (ru) Способы лечения неврологических расстройств
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
EA201691555A1 (ru) Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
EA201992832A1 (ru) Подкожное введение adamts13
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
EA202092540A1 (ru) Комбинации для лечения рака
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA201992004A1 (ru) Способы предотвращения или лечения офтальмологических заболеваний
EA202092045A1 (ru) Лечение и предупреждение преэклампсии
EA202090024A1 (ru) Способы лечения лептоменингеального заболевания
EA201992852A1 (ru) Схема дозирования тезетаксела и капецитабина
EA201650085A1 (ru) Способ лечения опухолевого заболевания и способ селективного ингибирования роста опухолевых клеток с помощью производного хиноксалин-1,4-диоксида
MX2019007236A (es) Metodos de administracion de hepcidina.
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
EA201991395A1 (ru) Новые композиции для лечения суставных нарушений